PRTA vs. XNCR, MNKD, BLTE, MIRM, ABCL, GMTX, COLL, DCPH, PIRS, and MGNX
Should you be buying Prothena stock or one of its competitors? The main competitors of Prothena include Xencor (XNCR), MannKind (MNKD), Belite Bio (BLTE), Mirum Pharmaceuticals (MIRM), AbCellera Biologics (ABCL), Gemini Therapeutics (GMTX), Collegium Pharmaceutical (COLL), Deciphera Pharmaceuticals (DCPH), Pieris Pharmaceuticals (PIRS), and MacroGenics (MGNX). These companies are all part of the "pharmaceutical preparations" industry.
Xencor (NASDAQ:XNCR) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.
In the previous week, Prothena had 1 more articles in the media than Xencor. MarketBeat recorded 4 mentions for Prothena and 3 mentions for Xencor. Prothena's average media sentiment score of 0.90 beat Xencor's score of -0.51 indicating that Xencor is being referred to more favorably in the media.
Xencor has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Prothena has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500.
Xencor currently has a consensus price target of $36.00, indicating a potential upside of 53.78%. Prothena has a consensus price target of $68.14, indicating a potential upside of 223.41%. Given Xencor's higher probable upside, analysts clearly believe Prothena is more favorable than Xencor.
Xencor has higher revenue and earnings than Prothena. Xencor is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.
Prothena received 107 more outperform votes than Xencor when rated by MarketBeat users. However, 72.85% of users gave Xencor an outperform vote while only 70.60% of users gave Prothena an outperform vote.
97.1% of Prothena shares are held by institutional investors. 5.0% of Xencor shares are held by insiders. Comparatively, 28.1% of Prothena shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Xencor has a net margin of -74.90% compared to Xencor's net margin of -160.91%. Prothena's return on equity of -18.67% beat Xencor's return on equity.
Summary
Xencor beats Prothena on 11 of the 18 factors compared between the two stocks.
Get Prothena News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Prothena Competitors List
Related Companies and Tools
